From Hit Identification to IND: Building a Tiered DMPK Strategy for Drug Development

Drug metabolism and pharmacokinetics (DMPK) testing plays a critical role in transitioning promising drug candidates from early discovery to clinical development. From the earliest stages of discovery through regulatory submission, DMPK data support important decisions related to candidate selection, lead optimization, safety assessment, and clinical translation. Rather than serving solely as a set of studies required to reach development milestones, DMPK is most effective when it is viewed as a strategic discipline that informs decision-making and helps guide program progression.

As therapeutic modalities continue to expand beyond traditional small molecules and development timelines become increasingly compressed, the importance of a well-planned DMPK strategy has grown significantly. A tiered DMPK approach—one that aligns specific studies with key program objectives and decision points—ensures that the most relevant data are generated when they are needed most. By integrating DMPK assessments throughout the development process, organizations can prioritize resources more effectively, identify liabilities earlier, reduce development risk, and build a stronger scientific package to support regulatory advancement from hit identification to IND and beyond. 

Why DMPK strategy matters early

During the discovery phase, developers are often evaluating large numbers of compounds with limited resources and compressed timelines. The goal at this stage is not to generate a comprehensive DMPK profile for every candidate, but rather to efficiently identify molecules with the greatest potential for success while eliminating those that present significant developability risks.

A strategic DMPK plan supports this objective by providing focused information on properties that are most likely to affect future performance and developability. Early assessments of metabolic stability, permeability, solubility, protein binding, and clearance can provide valuable insights into a compound’s absorption, distribution, metabolism, and elimination characteristics. Findings from these studies can guide lead optimization efforts, refine structure-activity relationships, and support the prioritization of the most promising candidates. By applying a tiered, risk-based approach, developers can focus resources on the most critical questions at each stage, improve decision-making efficiency, and reduce the likelihood of costly setbacks or attrition during preclinical and clinical development. 

Tier I: Hit-to-lead—Rapid screening and risk identification

The first tier of a DMPK strategy is designed to support rapid, data-driven decision-making during hit identification and lead selection. At this stage, studies are intentionally designed to be high-throughput, cost-effective, and low in material requirements, allowing teams to evaluate large numbers of compounds within short timelines. Typical assessments include solubility, lipophilicity, plasma stability, liver S9 or microsomal stability, plasma protein binding, permeability screening, and, where relevant, gastrointestinal stability evaluations.

The goal is straightforward: identify compounds that demonstrate favorable developability characteristics while efficiently filtering out candidates with clear pharmacokinetic liabilities. These early assays provide essential insights into a molecule’s potential absorption, metabolic stability, and systemic exposure, helping teams prioritize compounds most likely to succeed in downstream development.

However, DMPK data should never be interpreted in isolation. DMPK findings must be considered alongside potency, target biology, mechanism of action, and intended route of administration. A compound with moderate permeability, for example, may still represent a strong development candidate if it possesses exceptional potency, favorable tissue distribution, or is intended for a route of administration that minimizes absorption challenges. 

Tier II: Lead optimization—Building mechanistic understanding

Once a smaller group of promising candidates has emerged, the focus shifts from screening to lead optimization. At this stage, DMPK efforts move beyond evaluating developability and begin exploring the underlying mechanisms that drive pharmacokinetic behavior, systemic exposure, and overall drug disposition. Key questions addressed during this phase include: 

• What mechanisms are driving compound clearance?
• Where are the primary metabolic liabilities?
• Can structural modifications improve stability or exposure?
• What formulation approaches may enhance bioavailability or systemic exposure?

To address these questions, DMPK programs typically expand to include in vivo PK studies, metabolite identification, advanced permeability characterization, and investigations into metabolic and excretory clearance pathways. The resulting data provide the mechanistic understanding needed to make targeted optimization decisions. Rather than relying on trial-and-error approaches, development teams focus their efforts on modifications that directly address identified liabilities.

This stage also marks the beginning of translational planning. Evaluating how compounds behave across preclinical species helps establish the foundation for predicting human pharmacokinetics, selecting appropriate animal models, and identifying potential species-specific differences that may impact the interpretation of efficacy or safety data. 

Tier III: Candidate selection—Establishing translational confidence

As programs approach preclinical candidate nomination, the key question is no longer whether a molecule can be optimized, but whether a candidate possesses the robustness needed to successfully advance into regulatory development.

Studies conducted during this phase are intended to build confidence in the candidate’s overall pharmacokinetic profile, developability, and readiness for IND-enabling studies. DMPK activities during this phase are designed to provide a comprehensive understanding of the candidate and reduce uncertainties that could impact later development. Common studies include dose-escalation pharmacokinetic evaluations, cross-species metabolite profiling, excretion and mass balance investigations, formulation screening, and additional assessments to support translational and regulatory planning.

Together, these testing data provide a more complete picture of a candidate's PK profile and help answer several important questions: 

• Is the systemic exposure predictable across studies and species?
• Are the primary clearance and disposition pathways well characterized?
• Can the candidate support a practical and clinically relevant dosing regimen?
• Are formulation strategies available to meet future development and clinical requirements?

Discover What Metabolism Can Reveal

This infographic explores how real-time, live-cell metabolic measurements can help reveal the drivers of cellular response and provide deeper functional insight.
View Infographic

Advertisement

The data generated during this stage provide a more complete picture of the candidate’s pharmacokinetic behavior and support informed decision-making before formal IND-enabling activities commence. This phase serves as a critical bridge between discovery and development. 

Tier IV: IND-enabling studies—Supporting regulatory readiness

The final tier of a DMPK strategy focuses on generating the comprehensive data package required to support IND submission and the transition into clinical development. Unlike earlier stages, where studies are designed primarily to guide compound optimization and inform internal decision-making, IND-enabling activities must meet regulatory expectations and provide a thorough characterization of the candidate’s pharmacokinetic and absorption, distribution, metabolism, and excretion (ADME) profile.

At this stage, DMPK programs typically include repeat-dose PK assessments, drug-drug interaction evaluation, metabolite profiling and characterization, mass balance and excretion investigations, tissue distribution studies, and bioanalytical method development and qualification. Together, these studies provide a comprehensive understanding of the candidate’s ADME characteristics while generating the data necessary to support human dose projections, risk assessments, and first-in-human study design. The resulting package helps demonstrate that the candidate has been adequately characterized for clinical evaluation, supporting IND submission. 

Aligning DMPK with development milestones

Developers who adopt a structured, tiered DMPK strategy often enter this phase with greater confidence and fewer development challenges. By systematically identifying and addressing key liabilities during discovery and lead optimization, teams can focus IND-enabling studies on confirming and refining their understanding of the candidate rather than investigating unexpected findings. This proactive approach reduces uncertainty, streamlines development activities, and strengthens the overall scientific and regulatory foundation needed to advance a program into the clinic. 

Looking ahead

As therapeutic innovation continues to expand beyond traditional small molecules to include peptides, oligonucleotides, and other emerging modalities, the importance of strategic DMPK planning continues to grow. These increasingly diverse drug classes present unique ADME challenges that require thoughtful, stage-appropriate evaluation throughout development.

Successful drug development is not driven by generating more data alone, but by generating the right data at the right time. A tiered DMPK approach provides a framework for achieving this goal by aligning studies with key development decisions and program milestones. When implemented effectively, a tiered DMPK approach enables faster and more informed decision-making throughout the drug discovery and development continuum.